Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RNXT - RenovoRx, Inc.

IEX Last Trade
1.31
0.300   22.901%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:22:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$1.01
0.30
29.70%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
3.20%
1 Month
6.61%
3 Months
22.86%
6 Months
14.16%
1 Year
25.24%
2 Year
-28.33%
Key data
Stock price
$1.31
P/E Ratio 
0.00
DAY RANGE
$1.01 - $1.23
EPS 
$0.00
52 WEEK RANGE
$0.96 - $2.35
52 WEEK CHANGE
$29.00
MARKET CAP 
24.466 M
YIELD 
N/A
SHARES OUTSTANDING 
23.987 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.74
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$72,986
AVERAGE 30 VOLUME 
$97,493
Company detail
CEO: Shaun R. Bagai
Region: US
Website: www.renovorx.com
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

RenovoRx, Inc. focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.

Recent news